We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 05. | 장 마감 후 (AMC) | $0.81 | — | — | $71.47M | — | 예정 |
| FY2024 Q3 | 2023. 09. 30. | 시각 미정 | — | $0.97 | — | — | $144.6M | 보고됨 |
| FY2024 Q2 | 2023. 06. 30. | 시각 미정 | — | $0.63 | — | — | $97.19M |
Consensus PT $118.75 · 8 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 07. | Barrington Research | — | 의견 유지 | Outperform → Outperform | — | Barrington Research: Outperform |
| 2026. 05. 06. | Citizens | — | 의견 유지 | Market Outperform → Market Outperform | — | Citizens: Market Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2024 Q1 | 2023. 03. 31. | 시각 미정 | — | $0.27 | — | — | $47.08M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 281,978 | $30.78B | 0.03% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 143,308 | $11.62B | 0.02% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
Q3 2025 LeMaitre Vascular Inc Earnings Call Transcript - GuruFocus
Q3 2025 LeMaitre Vascular Inc Earnings Call Transcript GuruFocus
LeMaitre (LMAT) Q1 earnings report preview: What to look for - MSN
LeMaitre (LMAT) Q1 earnings report preview: What to look for MSN
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets - Yahoo Finance
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets Yahoo Finance
LeMaitre Vascular stock (US52567J1079): shares edge lower after recent earnings as sector focus shif - AD HOC NEWS
LeMaitre Vascular stock (US52567J1079): shares edge lower after recent earnings as sector focus shif AD HOC NEWS
AlphaQuest LLC Grows Position in LeMaitre Vascular, Inc. $LMAT - MarketBeat
AlphaQuest LLC Grows Position in LeMaitre Vascular, Inc. $LMAT MarketBeat